Effect of Combined Endurance Training and MitoQ on Cardiac Function and Serum Level of Antioxidants, NO, miR-126, and miR-27a in Hypertensive Individuals

Abstract

Objectives. Hypertension (HTN) is one of the most important risk factors for cardiovascular diseases. Despite advances in treatment and control of HTN, the prevalence of HTN is still increasing. MitoQ is a supplement that acts on mitochondria and attenuates reactive oxygen species (ROS), which plays an important role in cardiovascular health. miRNAs play an important role in the pathophysiology of HTN. We evaluated the effects of MitoQ supplementation and endurance training (ET), alone and in combination, on functional indices of the heart and serum levels of miR-126, miR-27a, antioxidants, and NO, in patients with HTN. Methods. In a double-blind randomized clinical trial, 52 male participants (age 40-55 years) were randomly divided into four groups ( n = 13 ) of placebo, MitoQ (20 mg/day, oral), ET (cycle ergometer, moderate intensity, 40-60% VO2 peak, heart rate 120-140 b/min, 45 min a day, three days/week for six weeks), and MitoQ+ET. Cardiac function indices were assessed by echocardiography before and after interventions. Results. Systolic blood pressure (SBP) significantly decreased in all intervention groups ( P < 0.001 ) while DBP ( P < 0.01 ) and LV hypertrophy ( P < 0.05 ) were significantly decreased only in the MitoQ+ET group. Serum levels of SOD, GPx, and NO and the level of miR-126 significantly increased in all treatment groups, while miR-27a reduced in the ET ( P < 0.05 ) and MitoQ+ET ( P < 0.01 ) groups. Conclusions. Compared to MitoQ and ET alone, their combination has more prominent improving effects on cardiac health and amelioration of BP in the patients with HTN. These effects are through miR-126 and miR-27a modulation and ameliorating mitochondrial ROS production.

Targeting the redox system for cardiovascular regeneration in aging

“…Additionally, promising outcomes have been observed with mitochondria‐targeted antioxidant (MitoQ), which comprises ubiquinol fused to a lipophilic cation (Rossman et al., 2018 ). MitoQ has shown high efficacy for vascular regeneration by promoting endothelial cell proliferation while concurrently downregulating oxidant‐regulated cell‐cycle arrest and senescence processes in both aged humans and mice (Gioscia‐Ryan et al., 2014 ; Huang et al., 2022 ; Masoumi‐Ardakani et al., 2022 ). Despite these encouraging findings, challenges persist in establishing efficient and potent antioxidant‐containing regimens for cardiovascular regeneration, particularly when it comes to conducting large‐scale trials.…”

Unraveling Therapeutic Opportunities and the Diagnostic Potential of microRNAs for Human Lung Cancer

“…Notably, elevated levels of a miRNA signature consisting of miR-1225-5p, miR-328, and miR-548 in serum have been associated with tumor progression and survival in NSCLC patients [ 141 ]. Conversely, a decrease in plasma levels of miR-126 is linked to chemotherapy resistance in NSCLC patients [ 142 ].…”

Mitochondria-Targeted Antioxidants as a Therapeutic Strategy for Chronic Obstructive Pulmonary Disease

“…MitoQ is currently the only commercially available MTA (available as a dietary supplement) and has shown significant success in Phase II clinical trials for patients with hypertension [ 101 ], Parkinson’s [ 102 ], and liver disease [ 103 ]. In addition, MitoQ has been shown to improve motor function [ 104 ] and vascular function in healthy older adults [ 105 ].…”